Evaxion A/S

Evaxion A/S (EVAX) Stock Analysis

$3.010

-0.134 (-4.44%)At close

Loading chart…
High
3.160
Open
3.150
VWAP
3.06
Vol
123.53K
Mkt Cap
15.53M
Low
3.010
Amount
377.99K
EV/EBITDA, TTM
-4.04

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

evaxion.ai

AI analysis of Evaxion A/S (EVAX)

hold

Currently, Evaxion Biotech A/S (EVAX) is not a strong buy due to its low current price of $3.01, which is significantly below the analyst price targets of $9 and $10. The stock's RSI of 30.46 indicates it is oversold, but the recent 5-day change of -9.06% raises concerns about momentum. The main risk is the company's net loss of $3.7 million in Q2 2026, which highlights ongoing cash burn and financial instability.

Valuation Metrics

The current forward P/E ratio for Evaxion A/S (EVAX) is 3.57, compared to its 5-year average forward P/E of -3.69.

Forward P/E

Overvalued
5Y Average P/E
-3.69
Current P/E
3.57
Overvalued
2.26
Undervalued
-9.65

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-1.47
Current EV/EBITDA
-4.04
Overvalued
-0.20
Undervalued
-2.73

Forward P/S

Fair
5Y Average P/S
11.58
Current P/S
5.63
Overvalued
28.12
Undervalued
-4.95

Alphio AI Price Scenarios for EVAX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%EVAX

$3.29

Scenario price

B

Base

Base · 50%EVAX

$3.03

Scenario price

B

Bear

Bear · 25%EVAX

$2.68

Scenario price

Events Timeline

2026-07-17 (ET)

08:00:00

Evaxion to Present Three-Year Clinical Data for EVX-01 at ESMO Congress

2026-07-12 (ET)

10:00:00

Evaxion Presents New Data Supporting EVX-V1 Vaccine Program

2026-04-17 (ET)

15:20:00

Evaxion Announces New Data Showing AI-Immunology Identifies Vaccine Targets

15:10:00

Evaxion Releases New Data Demonstrating Vaccine Development Potential

2026-04-07 (ET)

08:20:00

Evaxion Completes One-Year Extension of Phase 2 Trial for Personalized Cancer Vaccine EVX-01

Show More Events

News

Show More News

EVAX FAQ — answered by Alphio AI

Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections. It operates in the Healthcare sector.

Currently, Evaxion Biotech A/S (EVAX) is not a strong buy due to its low current price of $3.01, which is significantly below the analyst price targets of $9 and $10. The stock's RSI of 30.46 indicates it is oversold, but the recent 5-day change of -9.06% raises concerns about momentum. The main risk is the company's net loss of $3.7 million in Q2 2026, which highlights ongoing cash burn and financial instability.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started